Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aerosol L9-NC and Temozolomide in Ewing's Sarcoma and Solid Tumors with Lung Involvement
NCT00492141Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2006
- Primary completion
- May 2007
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of rubitecan in Ewing sarcoma and solid tumor, sponsored by University of Texas MD Anderson Cancer Center. Started Jun 2006; status: completed.
02
Drugs
rubitecan
03
Conditions
Ewing sarcomasolid tumor
Beyond the preview
Go deeper on NCT00492141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00492141.